Drug profile · INN
doxazosin mesylate
CARDURA
doxazosin mesylate (CARDURA) is a adrenergic receptor alpha-1 antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — doxazosin mesylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 6
- Data quality
- 0.89
Quick answer
doxazosin mesylate (CARDURA) is a adrenergic receptor alpha-1 antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Adrenergic receptor alpha-1 antagonist
Primary target: Adrenergic receptor alpha-1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is doxazosin mesylate?
doxazosin mesylate (CARDURA) is a adrenergic receptor alpha-1 antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for doxazosin mesylate?
CARDURA is a marketed brand name for doxazosin mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of doxazosin mesylate?
doxazosin mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.